HK1213521A1 - 多肽的應用 - Google Patents

多肽的應用

Info

Publication number
HK1213521A1
HK1213521A1 HK16101264.9A HK16101264A HK1213521A1 HK 1213521 A1 HK1213521 A1 HK 1213521A1 HK 16101264 A HK16101264 A HK 16101264A HK 1213521 A1 HK1213521 A1 HK 1213521A1
Authority
HK
Hong Kong
Prior art keywords
fix
methods
polypeptides
fix polypeptides
polypeptides fix
Prior art date
Application number
HK16101264.9A
Other languages
English (en)
Inventor
Glenn Pierce
Samantha Truex
Robert T Peters
Haiyan Jiang
Mark Brader
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HK1213521A1 publication Critical patent/HK1213521A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
HK16101264.9A 2012-09-25 2016-02-03 多肽的應用 HK1213521A1 (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261705607P 2012-09-25 2012-09-25
US201361759796P 2013-02-01 2013-02-01
US201361800163P 2013-03-15 2013-03-15
US201361811412P 2013-04-12 2013-04-12
US201361829755P 2013-05-31 2013-05-31
US201361839439P 2013-06-26 2013-06-26
US201361863859P 2013-08-08 2013-08-08
PCT/US2013/061747 WO2014052490A1 (en) 2012-09-25 2013-09-25 Methods of using fix polypeptides

Publications (1)

Publication Number Publication Date
HK1213521A1 true HK1213521A1 (zh) 2016-07-08

Family

ID=50388942

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101264.9A HK1213521A1 (zh) 2012-09-25 2016-02-03 多肽的應用

Country Status (5)

Country Link
US (3) US20150252345A1 (zh)
EP (2) EP2900328A4 (zh)
HK (1) HK1213521A1 (zh)
TW (3) TWI810729B (zh)
WO (1) WO2014052490A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
EP3453402B1 (en) 2012-01-12 2021-07-21 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
EP2900328A4 (en) 2012-09-25 2016-05-11 Biogen Ma Inc PROCESS FOR USE OF FIXED POLYPEPTIDES
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
CA2899089C (en) * 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
JP7058940B2 (ja) * 2014-03-24 2022-04-25 バイオベラティブ セラピューティクス インコーポレイテッド 凍結乾燥第ｉｘ因子製剤
JP7084878B2 (ja) * 2016-05-16 2022-06-15 武田薬品工業株式会社 抗第ＩＸ因子Ｐａｄｕａ抗体
EP3733199A1 (en) 2016-07-08 2020-11-04 CSL Behring Lengnau AG Subcutaneous administration of long-acting factor ix in humans
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) * 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
ES2963665T3 (es) * 2017-06-29 2024-04-01 CSL Behring Lengnau AG Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello
US11311676B2 (en) 2018-10-01 2022-04-26 Certa Dose, Inc. Syringe having dosing indications for prophylaxis and treatment
CN109439679A (zh) * 2018-10-09 2019-03-08 上海市儿童医院 一种高活性重组人凝血因子ix融合蛋白及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786726A (en) 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
AU735463B2 (en) 1997-02-14 2001-07-12 American Red Cross Expression of active human factor IX in mammary tissue of transgenic animals
BR9815975A (pt) 1998-07-31 2001-12-04 Wallace E Carroll Método e aparelho para a determinação defatores de terapia anticoagulante
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DK1278763T3 (da) 2000-04-28 2007-06-11 Inflazyme Pharm Ltd 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US20040254106A1 (en) 2001-09-04 2004-12-16 Carr Francis J. Modified factor ix
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
SI2298347T1 (sl) 2003-05-06 2016-03-31 Biogen Hemophilia Inc. Himerni proteini s faktorjem strjevanja krvi za zdravljenje hemostatske motnje
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7419982B2 (en) * 2003-09-24 2008-09-02 Wyeth Holdings Corporation Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts
CA2545539A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
NZ567685A (en) * 2005-11-01 2011-07-29 Wyeth Corp A Factor IX formulation for injection comprising sodium chloride
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
SI2004683T1 (sl) * 2006-03-24 2016-09-30 Biogen Hemophilia Inc. Pc5 kot encim za obdelavo propeptida faktorja ix
US20100222554A1 (en) * 2006-04-11 2010-09-02 Thomas Weimer Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides
EP2213733A3 (en) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP3896090B1 (en) 2006-06-14 2022-01-12 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
WO2008022151A1 (en) 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
EP2209487A4 (en) 2007-10-15 2012-06-20 Univ North Carolina VARIANTS OF HUMAN FACTOR IX WITH EXTENDED HALF-TIME
CA2721362A1 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
RU2010146387A (ru) 2008-04-16 2012-05-27 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Модифицированные полипептиды фактора ix и их применение
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
NZ588854A (en) 2008-04-24 2011-12-22 Celtic Pharma Peg Ltd Factor ix-polyethylene conjugates with extended half-lives
CA2732423A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
CN102164943A (zh) 2008-09-24 2011-08-24 稳定技术有限公司 使用糖和聚乙烯亚胺保存多肽的方法
MX2011006055A (es) * 2008-12-12 2011-07-04 Boehringer Ingelheim Int Anticuerpos anti-igf.
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
EP2353588B1 (en) * 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
PL2588666T3 (pl) 2010-07-01 2019-03-29 Archroma Ip Gmbh Wodne kompozycje do wybielania i cieniowania w zastosowaniach powłokowych
CN103140237A (zh) * 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
EP2900328A4 (en) 2012-09-25 2016-05-11 Biogen Ma Inc PROCESS FOR USE OF FIXED POLYPEPTIDES
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations

Also Published As

Publication number Publication date
TWI810729B (zh) 2023-08-01
US20150252345A1 (en) 2015-09-10
US20220064622A1 (en) 2022-03-03
WO2014052490A1 (en) 2014-04-03
US11225650B2 (en) 2022-01-18
TWI750197B (zh) 2021-12-21
TW201811361A (zh) 2018-04-01
EP2900328A1 (en) 2015-08-05
EP3542861A1 (en) 2019-09-25
TW202235102A (zh) 2022-09-16
TW201427685A (zh) 2014-07-16
EP2900328A4 (en) 2016-05-11
US20180002684A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
HK1250690A1 (zh) 方法
IL291571A (en) cx3cr1 binding polypeptides
HK1213521A1 (zh) 多肽的應用
HK1208363A1 (zh) 新方法
EP2852687A4 (en) METHODS FOR PREPARING A SAMPLE
EP2836211A4 (en) NOVEL PROCEDURE
GB201220474D0 (en) Polypeptides
ZA201406082B (en) Use of ccr3-inhibitors
EP2914293A4 (en) METHOD OF USE OF FVIII POLYPEPTIDE
IL236312A0 (en) Preparation of 18f-flucyclobin
EP2881113A4 (en) NEW APPLICATION OF POGOSTONE
GB2507760B (en) Methods
IL219244A0 (en) Splitting of user-lists
GB201208874D0 (en) Methods
EP2892529A4 (en) USES OF (-) - PERHEXILINE
HK1208553A1 (zh) 原產地鑒定
EP3560952C0 (en) VARIANT OF BPIFB4 PROTEIN
GB201204280D0 (en) Methods
GB201215942D0 (en) Method of treatent
EP2887938A4 (en) PROCESS FOR PREPARING TECOVIRIMAT
GB201208756D0 (en) Methods
GB201213672D0 (en) Protein
ZA201503833B (en) Method of hemoglobin-f determination
GB2552754B (en) Methods of positioning toilet components
TWM433525U (en) Structure of calorifier